In vivo safety evaluation of UP780, a standardized composition of aloe chromone aloesin formulated with an Aloe vera inner leaf fillet

Regulatory Toxicology and Pharmacology

Volumn 69, Issue 3, 2014, Pages 390-397

  Yimam, Mesfin ^a   Brownell, Lidia ^a   Jia, Qi ^a  

^a Unigen Inc   (United States)

Author keywords

Aloe vera; Aloesin; Qmatrix; Safety; Toxicity

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HERBACEOUS AGENT; SODIUM; UNCLASSIFIED DRUG; UP 780; UREA; ALOESIN; CHROMONE DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; PLANT EXTRACT;

ALOE VERA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOOD INTAKE; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MORTALITY; MOUSE; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; REPEATED DRUG DOSE; TOXICITY TESTING; ALOE; ANIMAL; DRUG EFFECTS; DRUG SURVEILLANCE PROGRAM; GLUCOSE BLOOD LEVEL; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SAFETY; WEIGHT GAIN;

ALOE; ALOE VERA; MUS;

ADMINISTRATION, ORAL; ALOE; ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CHROMONES; FEMALE; GLUCOSIDES; MALE; MICE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PLANT EXTRACTS; PLANT LEAVES; SAFETY; WEIGHT GAIN;

EID: 84904039269     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2014.05.001     Document Type: Article

References (23)

1. Agarwal O.P. Prevention of atheromatous heart disease. Angiology 1985, 36:485-492.
2. Aloecorp, Seattle-Wa. http://www.aloecorp.com/news-release/gras-status-given-qmatrix%C2%AE.
3. Bunyapraphatsara N., Yongchaiyudha S., Rungpitarangsi V., Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L juice. II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. Phytomedicine 1996, 3:245-248.
4. Cohen I.K., Diegelmann R.F., Lindblad W.J. Wound Healing: Biochemical & Clinical Aspects 1992, Saunders, Philadelphia.
5. Cosmetic Ingredient Review Expert Panel Final report on the safety assessment of AloeAndongensis Extract, Aloe Andongensis Leaf Juice, Aloe Arborescens Leaf Extract, Aloe Arborescens Leaf Juice, Aloe Arborescens Leaf Protoplasts, Aloe Barbadensis Flower Extract, Aloe Barbadensis Leaf, Aloe Barbadensis Leaf Extract, Aloe Barbadensis Leaf Juice, Aloe Barbadensis Leaf Polysaccharides, Aloe Barbadensis Leaf Water, Aloe Ferox Leaf Extract, Aloe Ferox Leaf Juice, and Aloe Ferox Leaf Juice Extract. Int. J. Toxicol. 2007, 26(Suppl 2):1-50.
6. Devaraj S., Yimam M., Brownell L.A., Jialal I., Singh S., Jia Q. Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab. Syndr. Relat. Disord. 2013, 11(1):35-40.
7. Fogleman R.W., Chapdelaine J.M., Carpenter R.H., McAnalley B.H. Toxicologic evaluation of injectable acemannan in the mouse, rat and dog. Vet. Hum. Toxicol. 1992, 34(3):201-205.
8. Fogleman R.W., Shellenberger T.E., Balmer M.F., Carpenter R.H., McAnalley B.H. Subchronic oral administration of acemannan in the rat and dog. Vet. Hum. Toxicol. 1992, 34(2):144-147.
9. Ghannam N., Kingston M., Al-Meshaal I.A., Tariq M., Parman N.S., Woodhouse N. The antidiabetic activity of Aloes: preliminary clinical and experimental observations. Horm. Res. 1986, 24(4):288-294.
10. Grindlay D., Reynolds T. The Aloe vera phenomenon: a review of the properties and modern uses of the leaf parenchyma gel. J. Ethnopharmacol. 1986, 16(2-3):117-151.
11. Hart L.A., van Enckevort P.H., van Dijk H., Zaat R., de Silva K.T., Labadie R.P. Two functionally and chemically distinct immunomodulatory compounds in the gel of Aloe vera. J. Ethnopharmacol. 1988, 23(1):61-71.
12. Herlihy J.T., Kim J.D., Kalu D.N., Nelson J.F., Ward W.F., Ikeno Y., Yu B.P. Effects of Aloe vera ingestion in the rat. II. Hormonal and metabolic characteristics. Phytother. Res. 1998, 12(5):355-360.
13. Huseini H.F., Kianbakht S., Hajiaghaee R., Dabaghian F.H. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Planta Med. 2012, 78(4):311-316.
14. Lynch B., Simon R., Roberts A. In vitro and in vivo assessment of the genotoxic activity of aloesin. Regul. Toxicol. Pharmacol. 2011, 61(2):215-221.
15. Lynch B., Simon R., Roberts A. Subchronic toxicity evaluation of aloesin. Regul. Toxicol. Pharmacol. 2011, 61(2):161-171.
16. Misawa E., Tanaka M., Nabeshima K., Nomaguchi K., Yamada M., Toida T., Iwatsuki K. Administration of dried Aloe vera gel powder reduced body fat mass in diet-induced obesity (DIO) rats. J. Nutr. Sci. Vitaminol. (Tokyo) 2012, 58(3):195-201.
17. Nasiff H.A., Fajardo F.R., Velez F. Effect of aloe on hyperlipidemia in patients with negative response to diet. Rev. Cubana Med. Gen. Integr. 1993, 9:43-51.
18. Natow A.J. Aloe vera, fiction or fact. Cutis 1986, 37(2). (pp. 106, 108).
19. Shah A.H., Qureshi S., Tariq M., Ageel A.M. Toxicity studies on six plants used in the traditional Arab system of medicine. Phytother. Res. 1989, 3(1):125-129.
20. Williams L.D., Burdock G.A., Shin E., Kim S., Jo T.H., Jones K.N., Matulka R.A. Safety studies conducted on a proprietary high-purity Aloe vera inner leaf fillet preparation. Qmatrix Regul. Toxicol. Pharmacol. 2010, 57(1):90-98.
21. Yagi A., Kanbara T., Morinobu N. Inhibition of mushroom-tyrosinase by Aloe extract. Planta Med. 1987, 53(6):515-517.
22. Yongchaiyudha S., Rungpitarangsi V., Bunyapraphatsara N., Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L juice. I. Clinical trial in new cases of diabetes mellitus. Phytomedicine 1996, 3:241-243.
23. Yu, B.P., Lee, K.Y., Identification of potent antioxidant from Aloe barbadensis. U.S. Patent No. 5, 939, 395.